Agenda Day 1

From 2010 onwards the Patents Country Court has
been comprehensively reformed and remodelled
into the Intellectual Property Enterprise Courtwhich
has affected the volume and types of
claims taken at the venue. While this has been
happening IP litigation at the High Court level has
been growing, highlighting that the UK remains an
important jurisdiction for IP dispute resolution. In
addition, preparations for the UK to host one of the
central divisions of the UPC have taken place. With
the above in mind, what might the post-Brexit IP
litigation landscape look like in the coming years?

img

Dr Sven Bostyn

Chair of the Expert Group on patent law in the field of biotechnology and genetic engineering
European Commission
img

Dr. Roya Ghafele

Director & Fellow
Oxfirst Ltd. and University Of Oxford
img

Dr Matthias Zigann

Presiding Judge
Munich Regional Court I, Germany
img

Gavin Lawson

Director, Intellectual Property
Gilead Sciences

8:45 AM - 9:45 AM How Will Life Sciences Companies Benefit From the UPC?

Kevin Mooney, Chairman, Drafting Committee for the Rules of Procedure for the Unified Patent Court
This session will include reasons for Life
Sciences companies to choose a unitary patent
as well as an update on the status of the rules of
procedure, such as potential filing problems for the
UK should it get refused from access to the UPC.

img

Kevin Mooney

Chairman
Drafting Committee for the Rules of Procedure for the Unified Patent Court